Drug Trial Radar · NCT03000946
Prevention of Postoperative Pancreatic Fistula by Somatostatin
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
655
Actual
Start
May 15, 2017
Primary completion
Feb 9, 2021
Study completion Feb 9, 2021
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- First posted
- Dec 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether somatostatin is more effective that octreotide in the prevention of post-pancreatectomy pancreatic fistula
Conditions
- Pancreatic Surgery
Interventions
SomatostatinDrug
Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
OctreotideDrug
Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- ≥ grade B or C postoperative pancreatic fistula as defined by the International Study Group of Pancreatic Fistula (ISGPF) classificationTime frame: 90 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
La Pitié Salpêtrière Hospital
Paris, France
Cochin Hospital
Paris, Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.